|1.||Schnuch, A: 2 articles (12/2005 - 03/2003)|
|2.||Uter, W: 2 articles (12/2005 - 03/2003)|
|3.||Qi, Jun: 1 article (04/2015)|
|4.||Schölz, Christian: 1 article (04/2015)|
|5.||Beli, Petra: 1 article (04/2015)|
|6.||Weinert, Brian T: 1 article (04/2015)|
|7.||Mann, Matthias: 1 article (04/2015)|
|8.||Jensen, Lars J: 1 article (04/2015)|
|9.||Choudhary, Chunaram: 1 article (04/2015)|
|10.||Cox, Jürgen: 1 article (04/2015)|
08/01/2006 - "To evaluate MMP-2 and -9 activities and the effect of non-steroidal anti-inflammatory drug (NSAID) bufexamac during remission from acute arthritis. "
08/01/2006 - "Results suggest that after acute arthritis of horses, elevated MMP activity is present in the joint, for several weeks, to a degree that could promote cartilage degradation, and treatment with the NSAID bufexamac is not likely to affect that. "
01/01/1972 - "[Bufexamac in the treatment of progressive polyarthritis. "
03/01/1987 - "Intra-articular treatment of inflammatory arthritis: double-blind trial comparing bufexamac with methylprednisolone acetate."
12/01/1999 - "injections of 20 or 40 mg of bufexamac, at weekly intervals, were effective in reducing clinical signs of lameness and SF activity of BGLUC associated with amphotericin B-induced carpal joint arthritis. "
|2.||Contact Dermatitis (Eczema, Contact)
01/01/1998 - "On patch testing, he exhibited severe contact sensitivity to bufexamac. "
01/01/1998 - "A photo Koebner phenomenon following contact dermatitis due to bufexamac is described. "
01/01/1996 - "[Severe contact dermatitis caused by bufexamac with large flap desquamation]."
01/01/1993 - "[Severe contact dermatitis caused by Parfenac cream]."
05/01/1987 - "Contact dermatitis due to bufexamac."
01/01/1975 - "Bufexamac: a review of its pharmacological properties and therapeutic efficacy in inflammatory dermatoses."
08/01/2012 - "In Australia bufexamac is mainly used for pharmacist-initiated local treatment of various dermatoses. "
01/01/2011 - "Patients with anogenital dermatoses were sensitized mainly to active agents of topical medicaments, in particular bufexamac (5.3%). "
05/01/2009 - "To our knowledge this is the first report on a bufexamac-induced pigmented purpuric dermatosis. "
09/01/1974 - "Bufexamac in the treatment of skin diseases in general practice."
|5.||Epidermolysis Bullosa Simplex (Epidermolysis Bullosa Herpetiformis Dowling Meara)
|3.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
|4.||Amphotericin B (Amphotericin)
|7.||Fluocinolone Acetonide (Capex)
|8.||Triamcinolone Acetonide (Azmacort)